PTC Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ. 

CEO
Matthew B. Klein
CEOMatthew B. Klein
Employees
939
Employees939
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
1998
Founded1998
Employees
939
Employees939

PTCT Key Statistics

Market cap
6.17B
Market cap6.17B
Price-Earnings ratio
9.03
Price-Earnings ratio9.03
Dividend yield
Dividend yield
Average volume
1.10M
Average volume1.10M
High today
$77.39
High today$77.39
Low today
$75.65
Low today$75.65
Open price
$76.19
Open price$76.19
Volume
1.45M
Volume1.45M
52 Week high
$87.50
52 Week high$87.50
52 Week low
$35.95
52 Week low$35.95

Stock Snapshot

As of today, PTC Therapeutics(PTCT) shares are valued at $76.85. The company's market cap stands at 6.17B, with a P/E ratio of 9.03.

During the trading session on 2026-01-08, PTC Therapeutics(PTCT) shares reached a daily high of $77.39 and a low of $75.65. At a current price of $76.85, the stock is +1.6% higher than the low and still -0.7% under the high.

Trading activity shows a volume of 1.45M, compared to an average daily volume of 1.1M.

Over the past 52 weeks, PTC Therapeutics(PTCT) stock has traded between a high of $87.50 and a low of $35.95.

Over the past 52 weeks, PTC Therapeutics(PTCT) stock has traded between a high of $87.50 and a low of $35.95.

PTCT News

TipRanks 9h
PTC Therapeutics price target raised to $90 from $78 at Morgan Stanley

Morgan Stanley raised the firm’s price target on PTC Therapeutics (PTCT) to $90 from $78 and keeps an Overweight rating on the shares. The firm sees a continuat...

Simply Wall St 1d
How Royalty Sale, Sephience Approval and CEO Share Sale At PTC Therapeutics Has Changed Its Investment Story

Recently, PTC Therapeutics amended its royalty purchase agreement with Royalty Pharma to fully monetize a non-core royalty asset for an upfront US$240 million p...

How Royalty Sale, Sephience Approval and CEO Share Sale At PTC Therapeutics Has Changed Its Investment Story
Simply Wall St 3d
A Look At PTC Therapeutics Valuation After Strong Recent Shareholder Returns

PTC Therapeutics (PTCT) has drawn investor attention after recent trading left the share price at US$76.74. This has prompted a closer look at how its rare dise...

A Look At PTC Therapeutics Valuation After Strong Recent Shareholder Returns

Analyst ratings

60%

of 15 ratings
Buy
60%
Hold
33.3%
Sell
6.7%

More PTCT News

TipRanks 6d
PTC Therapeutics CEO Makes Bold Move With Major Stock Sale

New insider activity at PTC Therapeutics ( (PTCT) ) has taken place on January 2, 2026. Claim 70% Off TipRanks This Holiday Season Unlock hedge fund-level data...

People also own

Based on the portfolios of people who own PTCT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.